Haemonetics (HAE) Common Equity (2010 - 2026)

Haemonetics has reported Common Equity for 17 years, with the latest figure at $837.1 million in Q2 2026.

• On a quarterly basis, Common Equity fell 5.12% year-over-year to $837.1 million in Q2 2026; TTM through Jun 2026 was $837.1 million, a 5.12% decrease from a year earlier, with the FY2026 full-year figure at $796.3 million, down 2.99% from the prior year.
• Common Equity was $837.1 million for Q2 2026 at Haemonetics, up from $796.3 million in the prior quarter.
• The five-year high for Common Equity was $960.0 million in Q1 2024, with the low at $729.0 million in Q4 2022.
• Average Common Equity over 5 years is $843.3 million, with a median of $849.2 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Common Equity advanced 22.59% in 2023, then dropped 14.49% in 2025.
• Over 5 years, Common Equity stood at $776.0 million in 2022, then climbed by 21.57% to $943.3 million in 2023, then dropped by 3.86% to $906.9 million in 2024, then gained by 0.51% to $911.5 million in 2025, then fell by 8.16% to $837.1 million in 2026.
• The last three Common Equity figures came in at $837.1 million (Q2 2026), $796.3 million (Q1 2026), and $911.5 million (Q4 2025), per Business Quant data.